Stem Cell Mobilization for T Cell Lymphocytopenia

Recruiting at 1 trial location

Overseen By Irini Sereti, M.D.

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Must not be taking: Lithium, Anticoagulants, Immunomodulators, others

Disqualifiers: Autoimmune conditions, Leukemia, Hepatitis, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 7

Duration: 1 week

40 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand more about idiopathic CD4 lymphocytopenia (ICL), a rare condition where low CD4 T cell counts make individuals prone to infections. The study will test two treatments, Filgrastim (a granulocyte colony-stimulating factor) and Plerixafor, to release certain blood cells (hematopoietic progenitor cells) into the bloodstream for further study. Participants will include those with a history of ICL and healthy volunteers who meet specific health criteria, such as having a good blood count and the ability to stay in the hospital for a short period. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Do I need to stop taking my current medications for the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you are currently receiving lithium or have used systemic immune-modulatory agents in the past 6 months. It's best to discuss your specific medications with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Previous studies have shown that plerixafor is generally well-tolerated. Most side effects, such as nausea and diarrhea, were mild. Serious side effects, like blocked blood flow, were rare and occurred with higher doses. Filgrastim, also known as NEUPOGEN®, is commonly used to increase white blood cells in people with low counts. It has shown safety, with some common side effects like rash and allergic reactions. Both treatments have a strong safety record, making them promising options for helping stem cells move into the blood. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments for T cell lymphocytopenia because they offer new ways to boost stem cell mobilization. Filgrastim, a granulocyte colony-stimulating factor, is used to ramp up white blood cell production effectively, which might lead to better stem cell yields, especially in lighter-weight donors. Plerixafor, on the other hand, works by blocking a specific protein that holds stem cells in the bone marrow, allowing more stem cells to enter the bloodstream before collection. This combination could enhance the efficiency and effectiveness of stem cell collection compared to current methods, potentially leading to improved treatment outcomes.

What evidence suggests that this trial's treatments could be effective for T cell lymphocytopenia?

In this trial, participants will receive either Plerixafor or Filgrastim as separate treatment options. Research has shown that combining Plerixafor with granulocyte colony stimulating factor (G-CSF, also called Filgrastim) can significantly increase the number of CD34+ cells in the blood. Specifically, studies found that Plerixafor doubled CD34+ cell counts when used with G-CSF, compared to G-CSF alone. Plerixafor effectively mobilizes these crucial blood-forming cells, which help build a strong immune system. Filgrastim also aids in moving these cells into the bloodstream. Together, these treatments may help increase important immune cells in people with idiopathic CD4 lymphocytopenia, a condition characterized by low CD4 T cell counts. ^{6 7 8 9 10}

Who Is on the Research Team?

Irini Sereti, M.D.

Principal Investigator

National Institute of Allergy and Infectious Diseases (NIAID)

Are You a Good Fit for This Trial?

This trial is for adults aged 18-65 with a rare condition called Idiopathic CD4 Lymphocytopenia (ICL), which involves very low levels of certain immune cells. Participants must have documented ICL, be HIV negative, and not currently have any serious illnesses or conditions that could interfere with the study. They should also agree to use effective birth control during the study.

Inclusion Criteria

ICL patients with documented history of idiopathic CD4 lymphocytopenia

Willingness to have blood samples stored for future research

Established primary care provider

Exclusion Criteria

I need blood thinners other than aspirin or clopidogrel.

Hepatitis B and C seropositivity

Thrombocytopenia (platelets <100,000 cells/microL)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

12 weeks

Treatment

Participants receive G-CSF for 5 days with hospitalization on Day 4 for plerixafor injection followed by apheresis on Day 5

1 week

Daily visits for 5 days, including hospitalization on Day 4

Follow-up

Participants return for examinations and blood draws to monitor safety and effectiveness

1 week

2 visits (in-person) on Days 8 and 12

What Are the Treatments Tested in This Trial?

Interventions

• Filgrastim
• Plerixafor

Trial Overview The trial tests Plerixafor and Filgrastim's ability to mobilize stem cells in patients with ICL compared to healthy volunteers. These drugs may help move important progenitor cells into the bloodstream for collection and research on T cell development within mice models.

How Is the Trial Designed?

Group I: Plerixafor Experimental Treatment 1 Intervention

ICL and healthy volunteers will be given 0.24 mg/kg as a single dose (maximum dose: 40 mg) 11 hours prior to apheresis

Group II: Filgrastim Experimental Treatment 1 Intervention

ICL and healthy volunteers will be given 10 microgram/kg daily for 5 days administered according to a vial-based algorithm to reduce wastage and increase the G-CSF dose given to lighter-weight donors to improve CD34+ yields

Filgrastim is already approved in United States, European Union, Canada, Japan for the following indications:

Approved in United States as Neupogen for:

• Neutropenia
• Acute Myeloid Leukemia
• Bone Marrow Transplantation
• Chronic Neutropenia
• Leukemia
• Myelodysplastic Syndromes

Approved in European Union as Neupogen for:

• Neutropenia
• Acute Myeloid Leukemia
• Bone Marrow Transplantation
• Chronic Neutropenia
• Leukemia
• Myelodysplastic Syndromes

Approved in Canada as Neupogen for:

• Neutropenia
• Acute Myeloid Leukemia
• Bone Marrow Transplantation
• Chronic Neutropenia
• Leukemia
• Myelodysplastic Syndromes

Approved in Japan as Neupogen for:

• Neutropenia
• Acute Myeloid Leukemia
• Bone Marrow Transplantation
• Chronic Neutropenia
• Leukemia
• Myelodysplastic Syndromes

Who Is Running the Clinical Trial?

National Institute of Allergy and Infectious Diseases (NIAID)

Lead Sponsor

Trials

3,361

Recruited

5,516,000+

Published Research Related to This Trial

Plerixafor combined with G-CSF mobilizes a greater total number of nucleated and mononuclear cells compared to G-CSF alone, but results in a smaller proportion of CD34+ cells, which are crucial for stem cell transplants.

Patients mobilized with plerixafor required significantly more storage bags for their stem cell products (15 bags) compared to those mobilized with G-CSF alone (9 bags), potentially leading to logistical challenges and increased storage costs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs. Tanhehco, YC., Adamski, J., Sell, M., et al.[2021]

In a prospective randomized trial involving 97 patients with multiple myeloma and non-Hodgkin lymphoma, tbo-filgrastim was found to be not inferior to filgrastim in terms of stem cell mobilization efficacy, with a mean collection of 11.6 CD34+ cells/kg compared to 10.0 CD34+ cells/kg for filgrastim.

Both tbo-filgrastim and filgrastim showed similar safety profiles, indicating that tbo-filgrastim can be a safe and effective alternative to filgrastim for stem cell mobilization in patients undergoing autologous hematopoietic stem cell transplantation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. Bhamidipati, PK., Fiala, MA., Grossman, BJ., et al.[2021]

A retrospective study of adverse drug reactions from 1991 to 2018 found that filgrastim biosimilars, such as Grasin® and Zarzio®, reported higher rates of specific side effects compared to the originator Neupogen®, indicating potential differences in safety profiles.

The study revealed that some biosimilars, like Zarzio® and Tevagrastim®, had significant reports of drug ineffectiveness, suggesting that their efficacy may not match that of the original filgrastim, highlighting the need for further large-scale studies to confirm these findings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data. Rastogi, S., Shukla, S., Sharma, AK., et al.[2020]

Filgrastim significantly reduces the incidence of febrile neutropenia and severe neutropenia in patients undergoing chemotherapy, with relative risks of 0.63 and 0.50, respectively, based on a systematic review of 25 studies involving 1194 articles.

The most common adverse effect reported with filgrastim treatment is bone pain, which has a relative risk of 2.61, indicating it is a notable side effect to consider when using this medication.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Dale, DC., Crawford, J., Klippel, Z., et al.[2022]

In a Phase I clinical trial involving 56 healthy subjects, the recombinant filgrastim product Leucostim® demonstrated comparable pharmacokinetic and pharmacodynamic profiles to the reference product Neupogen®, indicating its potential as a biosimilar treatment for neutropenia.

Both products showed similar safety profiles, with no serious adverse events reported, reinforcing the safety of using Leucostim® as an alternative to Neupogen®.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers. Choi, C., Yoo, BW., Kim, CO., et al.[2022]

Filgrastim-sndz (Zarxio) became the first biosimilar approved by the FDA in the US on March 6, 2015, for all indications of its reference product, Amgen's Neupogen.

This biosimilar is primarily used to treat neutropenia in cancer patients undergoing chemotherapy, demonstrating its efficacy in managing a common side effect of cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Totality of the evidence at work: The first U.S. biosimilar. Holzmann, J., Balser, S., Windisch, J.[2022]

Pegfilgrastim is as effective or even more effective than filgrastim in reducing chemotherapy-induced neutropenia, making it a strong option for patients undergoing cancer treatment.

One of the key benefits of pegfilgrastim is that it can be administered just once per chemotherapy cycle, which may improve patient compliance and enhance their quality of life.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Morishita, M., Leonard, RC.[2022]

A study involving 40 patients with multiple myeloma showed that the biosimilar filgrastim is as effective as the originator G-CSF in mobilizing peripheral blood stem cells, with no significant differences in the number of CD34+ cells collected.

Both biosimilar and originator G-CSF groups had similar rates of mobilization failure (2.5% vs. 2.7%) and comparable outcomes in hematopoietic recovery and transplant-related toxicities, indicating the biosimilar's safety and efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Martino, M., Recchia, AG., Moscato, T., et al.[2018]

In a study of 243 donors for allogeneic hematopoietic stem cell transplantation, biosimilar filgrastim (Leucostim®) was found to be equally effective as original filgrastim (Neupogen®) and Lenograstim (Granocyte®) in mobilizing CD34(+) cells, which are crucial for stem cell transplants.

The median number of collected CD34(+) cells was similar across all three G-CSF agents, indicating that the choice of agent does not significantly impact the effectiveness of stem cell mobilization in this context.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors. Sivgin, S., Karakus, E., Keklik, M., et al.[2018]

A study comparing the originator filgrastim (Neupogen) with three EU-approved biosimilars showed that all products maintained a high level of similarity in quality attributes, including protein content and impurity levels, up to 5 years post-approval.

The biological activity of the biosimilars was comparable to the reference standard, indicating that they are equally effective in treating neutropenia-related conditions in cancer patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Analytical Comparison of the Originator Granulocyte-colony Stimulating Factor Filgrastim and its Biosimilars. Orlik, G., Khan, MA., Grieb, P.[2019]

In a study involving 348 breast cancer patients undergoing chemotherapy, the new G-CSF XM02 was found to significantly reduce the duration of severe neutropenia compared to a placebo, with a mean duration of 1.1 days for both XM02 and Neupogen, versus 3.9 days for placebo.

XM02 demonstrated similar safety profiles to Neupogen, indicating that it is an effective alternative for managing chemotherapy-induced neutropenia without increased toxicity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. del Giglio, A., Eniu, A., Ganea-Motan, D., et al.[2022]

In a study of 250 multiple myeloma patients, the mobilization efficiency of the G-CSF variants filgrastim, lenograstim, and the biosimilar Filgrastim Hexal was found to be similar, with all but one patient reaching the target of at least 2×10^6 CD34+ cells/kg body weight.

No significant differences in CD34+ cell mobilization and collection yields were observed among the three G-CSF variants, indicating that the biosimilar Filgrastim Hexal is as effective as the originator drugs for peripheral blood stem cell mobilization.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma. Lisenko, K., Baertsch, MA., Meiser, R., et al.[2018]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC6934574/

Efficacy and Safety of Nivestim Versus Neupogen for ... Nivestim was found to be safe and non-inferior to Neupogen for chemo-mobilization of stem cells for autoSCT, and associated with lower cost and shorter length ...

2. sciencedirect.com sciencedirect.com/science/article/abs/pii/S1473050225000473

Comparison of the efficacy and total cost of peripheral ... This retrospective study evaluated the efficacy and total cost of switching from filgrastim (Neupogen) to its biosimilar, filgrastim-aafi (Nivestym), for ...

3. ashpublications.org ashpublications.org/blood/article/142/Supplement%201/3523/502005/Comparison-of-Biosimilar-Filgrastim-Nivestym

Comparison of Biosimilar Filgrastim (Nivestym) Versus ... Conclusions: Biosimilar G-CSF (Nivestym) demonstrated similar efficacy for peripheral blood stem cell mobilization compared to the originator G- ...

4. jhoponline.com jhoponline.com/issue-archive/2022-issues/june-2022-vol-12-no-3/comparing-single-center-outcomes-between-reference-and-biosimilar-granulocyte-colony-stimulating-factor-drugs-used-for-autologous-stem-cell-mobilization

Comparing Single-Center Outcomes Between Reference ... The use of a biosimilar G-CSF drug demonstrated mobilization outcomes similar to the reference drug in patients who had undergone ASCT.

5. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/32686616/

Efficacy of a conversion from filgrastim to filgrastim-sndz in ... The conversion from filgrastim to filgrastim-sndz afforded patients similar efficacy for mobilization in stem cell transplant at a reduced cost.

6. neupogenhcp.com neupogenhcp.com/important-safety-information

Important Safety Information and Indications White blood cell counts ≥ 100,000/mm3 were observed in about 2% of patients who received NEUPOGEN® at dosages > 5 mcg/kg/day; Discontinue NEUPOGEN® if the ...

7. accessdata.fda.gov accessdata.fda.gov/drugsatfda_docs/label/2010/103353_5127lbl.pdf

NEUPOGEN (Filgrastim) - accessdata.fda.gov NEUPOGEN® has been shown to be safe and effective in accelerating the recovery of neutrophil counts following a variety of chemotherapy regimens. In a phase 3 ...

8. webmd.com webmd.com/drugs/2/drug-7729/filgrastim-injection/details

Filgrastim: Uses, Side Effects, Interactions, Pictures, ... Filgrastim is commonly used to help prevent infection in people who have low levels of white blood cells, also called neutropenia.

9. rxlist.com rxlist.com/zarxio-drug.htm

Zarxio (Filgrastim-sndz Injection): Side Effects, Uses, ... Adverse reactions with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included rash and hypersensitivity. Adverse ...

10. labeling.pfizer.com labeling.pfizer.com/ShowLabeling.aspx?id=10899

full prescribing information for NIVESTYM The safety of filgrastim products in chronic myeloid leukemia (CML) and myelodysplasia has not been established.